Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

SHA:688076 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	988.01	571.39	749.08	399.96	591.88	69.71
Trading Asset Securities	93	208	-	43.01	87.13	80
Cash & Short-Term Investments	1,081	779.39	749.08	442.98	679.01	149.71
Cash Growth	63.41%	4.05%	69.10%	-34.76%	353.54%	157.70%
Accounts Receivable	687.5	539.21	297.26	251.29	143.37	109.12
Other Receivables	8.31	7.92	3.27	1.19	1.05	5.05
Receivables	695.81	547.13	300.53	252.48	144.41	114.17
Inventory	841.07	584.04	377.17	323.48	250.82	185
Other Current Assets	126.48	94.97	67.98	33.53	29.86	39.03
Total Current Assets	2,744	2,006	1,495	1,052	1,104	487.91
Property, Plant & Equipment	2,585	1,892	1,405	988.47	706.55	613.74
Long-Term Investments	241.53	215.04	117.5	94.5	-	-
Goodwill	156.34	156.34	156.34	156.34	160.92	162.2
Other Intangible Assets	174.13	108.19	112.1	98.18	88.57	87.11
Long-Term Deferred Tax Assets	119.68	88.27	46.65	28.13	16.63	26.5
Long-Term Deferred Charges	310.57	203.2	41.03	38.77	15.66	12.02
Other Long-Term Assets	358.52	409.4	173.84	65.44	34.46	6.11
Total Assets	6,690	5,078	3,547	2,522	2,127	1,396
Accounts Payable	596.6	159.7	141.93	87.61	72.36	24.49
Accrued Expenses	54.81	149.12	86.14	48.49	43.99	32.98
Short-Term Debt	1,140	1,044	546.02	318.73	77.27	177.95
Current Portion of Long-Term Debt	183.2	117.89	40.08	-	-	32
Current Portion of Leases	-	9.79	5.29	1.47	3.64	-
Current Income Taxes Payable	18.36	19.35	11.47	5.37	-	12.85
Current Unearned Revenue	27.27	61.21	8.39	6.85	26.17	13.34
Other Current Liabilities	30.66	191.83	134.01	82.8	51.96	88.6
Total Current Liabilities	2,051	1,753	973.34	551.32	275.4	382.21
Long-Term Debt	1,228	445.21	286.49	-	-	37.95
Long-Term Leases	32.9	25.75	17.18	-	2.74	-
Long-Term Unearned Revenue	146.24	55.99	31.46	35.32	21.74	4.4
Long-Term Deferred Tax Liabilities	7.98	8.61	10.16	10.77	4.26	4.99
Other Long-Term Liabilities	90.25	107.43	39.31	-	14	-
Total Liabilities	3,556	2,396	1,358	597.41	318.14	429.55
Common Stock	316.05	219.78	213.18	213.18	213.18	159.89
Additional Paid-In Capital	1,754	1,598	1,341	1,319	1,318	641.03
Retained Earnings	1,057	792.51	495.37	374.95	277.82	162.43
Comprehensive Income & Other	-17.92	50.11	120.23	3.33	2.2	-
Total Common Equity	3,109	2,660	2,170	1,910	1,811	963.34
Minority Interest	24.86	21.95	19.04	14.66	-2.61	2.68
Shareholders' Equity	3,134	2,682	2,189	1,925	1,809	966.02
Total Liabilities & Equity	6,690	5,078	3,547	2,522	2,127	1,396
Total Debt	2,584	1,642	895.07	320.19	83.65	247.89
Net Cash (Debt)	-1,503	-863.06	-145.98	122.79	595.36	-98.18
Net Cash Growth	-	-	-	-79.38%	-	-
Net Cash Per Share	-4.86	-2.81	-0.49	0.41	2.21	-0.44
Filing Date Shares Outstanding	316.05	307.69	298.46	298.46	298.46	223.84
Total Common Shares Outstanding	316.05	307.69	298.46	298.46	298.46	223.84
Working Capital	693.33	252.82	521.43	501.15	828.71	105.7
Book Value Per Share	9.84	8.65	7.27	6.40	6.07	4.30
Tangible Book Value	2,779	2,396	1,902	1,656	1,562	714.04
Tangible Book Value Per Share	8.79	7.79	6.37	5.55	5.23	3.19
Buildings	-	516.19	504.29	476.24	376.08	339.12
Machinery	-	1,603	1,123	652.13	529	435.18
Construction In Progress	-	339.92	185.96	180.11	34.85	9.88

Source: S&P Global Market Intelligence. Standard template. Financial Sources.